Compare Cytokinetics Inc (CYTK) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Cytokinetics Inc trades at $62.92 (market cap $8.62B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.33 (market cap $561.25M). The key difference: Cytokinetics Inc is far larger — about 15.4× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and First Trust NASDAQ Clean Edge Green Energy Idx Fd is more actively traded (323,550 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| CYTK | QCLN | |
|---|---|---|
Market Cap | $8.62B | $561.25M |
Volume | 2,594,626 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $87.26 | $68.47 |
52-Week Low | $54.76 | $41.10 |
Typical Hold Time | 19 Days | 50 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
QCLN trades at $49.44, down 2.62% today but maintains a bullish technical outlook with strong moving average support. The clean energy ETF benefits from geopolitical tensions accelerating renewable energy adoption globally. Recent news highlights increased data center energy demand and political focus on clean energy policies as key growth catalysts.
The ETF's performance remains tied to U.S. political outcomes and federal energy policy, with recent outperformance against major indices. Key risks include policy uncertainty and market volatility, while institutional interest grows amid global energy security concerns and the ongoing energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
